This bill requires the Department of Health and Human Services to provide reimbursement under the MaineCare program for glucagon-like peptide-1 receptor agonists that are approved by the federal Food and Drug Administration for the treatment of obesity. The department must restrict reimbursement to medications prescribed by a primary care provider or a bariatric specialist and must require a prior authorization of the medication.